LASS1 polyclonal antibody (A01) H00010715-A01 from Abnova Corporation

Published Figures

Register or Sign In to View Figures.

Cancers (Basel)
September 16 2022

Fig 1: (A) Schematic showing the sphingolipid metabolic pathway where serine palmitoyl transferase (SPT1–2), 3–Ketosphinganine reductase (KDSR), Dihydroceramide desaturase (DEGS1–2), Ceramide synthases (CERS1–6), Ceramide transferase (CERT), Ceramide 1-phosphate phosphatase (C1PP), N–Acylsphingosine amidohydrolase (ASAH1, ASAH2), Alkaline ceramidase (ACER1, ACER3), Sphingosine–1–phosphate kinase (SPHK1, 2), Sphingosine–1–phosphate phosphatase (S1PP), Sphingosine–1–phosphate lyase (S1PL), Ceramide Kinase (CERK), Sphingomyelin Phosphodiesterase (SMPD1–4), Sphingomyelin synthase (SMS1–2), UDP-Glucose ceramide glucosyltransferase (UGCG), ß–glucocerebrosidase (GBA1), ß–galactosidase (GLB1), ß–1,4–Galactosyltransferase 6 (B4GALT6) are the enzymes of the pathway. (B) Schematic showing major subtypes of breast cancer, such as luminal A, luminal B, luminal B with HER2 overexpression (also called triple-positive, TPBC), triple-negative (TNBC)/Basal-like, and HER2+.
Register or Sign In to View Figures.

Cell Death & Disease
February 10 2021

Fig 2: Overexpression of CERS2 transcript (AS1) decreases expression of very-long-chain ceramides in BT-474 cells.A Change in expression of all ceramide synthases (CERS1-6) (mean ± SD, n = 4) in BT-474 cells transfected with empty vector, BT-474 (+Vector), full-length protein-coding CERS2 OE (PC), and alternatively spliced transcript coding CERS2 OE (AS1) constructs. Expression was normalized to ß-actin. B Immunoblot showing the expression of CERS2 in BT-474, BT-474 (+Vector), CERS2 OE (PC), and CERS2 OE (AS1) cells by western blot analysis. Protein corresponding to PC transcript is marked by blue asterisk, and to AS1 transcript by red asterisk. C Heat map showing the average fold change in levels of ceramides (C16:0, C18:0, C20:0, C22:0, C24:0, and C24:1) in BT-474 cells transfected with CERS2 OE (PC) and CERS2 OE (AS1) with respect to BT-474 cells. D–F Absolute quantification of ceramides (mean ± SD, n = 4) show significant decrease in C22:0 (D), C24:0 (E), and C24:1 (F) ceramides in CERS2 OE (AS1) cells as compared to CERS2 OE (PC) cells. G–I Fold change (mean ± SD, n = 4) in deuterium-labeled ceramides (pmol/mg protein) in HEK 293T cells transfected with CERS2 OE (PC) and CERS2 OE (AS1) constructs using HEK 293T cells as a control shows significant decrease in C24:0 Ceramide (Cer)-d7 (G) and C24:1 Cer-d7 (H) ceramides with no significant change in C16:0 Cer-d7 (I) ceramides in CERS2 OE (AS1) cells as compared to CERS2 OE (PC) cells. Data in A, D–I were analyzed using ANOVA test.

Be the first to write a review!

Citations:

(4)

Figures:

Supplier Page

Supplier Page from
Abnova Corporation for
LASS1 polyclonal antibody (A01)

The LASS1 polyclonal antibody (A01) from Abnova Corporation is a Mouse Polyclonal antibody to ceramide synthase 1, and CERS1. This antibody recognizes Human antigen. The LASS1 polyclonal antibody (A01) has been validated for the following applications: EIA, Immunoassay, ELISA, and Western Blot.

Description

Mouse polyclonal antibody raised against a partial recombinant LASS1

Cancers (Basel)

Cell Death & Disease

LASS1 polyclonal antibody (A01) from Abnova Corporation

Description

Sequence

Abnova Corporation

Citations (4)

Reviews

LASS1 polyclonal antibody (A01) from Abnova Corporation

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map